Wallingford, CT, United States of America

Eric P Gillis

USPTO Granted Patents = 37 (Patent Applications = 20)

CIPO Patents = 3 (Patent Applications = 14)

EPO Patents = 18 (Patent Applications = 21)

Average Co-Inventor Count = 4.2

ph-index = 8

Forward Citations = 126(Granted Patents)

Location History:

Champaign, IL (US) (2011 - 2012)
Wallingford, CT (US) (2012 - 2020)
Cheshire, CT (US) (2016 - 2020)
Branford, CT (US) (2022 - 2023)

Company Filing History:

17 out of 3,681

Bristol-myers Squibb Compnay

patents

17 out of 2,340

University of Illinois

patents

3 out of 42

Viiv Healthcare UK (no.5) Limited

patents

Years Active: 2011-2024

Loading Chart...

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12129255 - Pyrido [2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication (2024-10-29),

2. 11541055 - Inhibitors of human immunodeficiency virus replication (2023-01-03),

3. 11505543 - 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication (2022-11-22),

4. 10752577 - Automated synthesis of small molecules using chiral, non-racemic boronates (2020-08-25),

5. 10538555 - Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions (2020-01-21),

6. 10450347 - Immunomodulators (2019-10-22),

7. 10358463 - Immunomodulators (2019-07-23),

8. 10239824 - Automated synthesis of small molecules using chiral, non-racemic boronates (2019-03-26),

9. 10143746 - Immunomodulators (2018-12-04),

10. 9944678 - Immunomodulators (2018-04-17),

11. 9908900 - Methods for forming protected organoboronic acids (2018-03-06),

12. 9879046 - Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions (2018-01-30),

13. 9868743 - Macrocyclic molecules as HCV entry inhibitors (2018-01-16),

14. 9862733 - Apparatus and methods for the automated synthesis of small molecules (2018-01-09),

15. 9850283 - Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions (2017-12-26),

Certainly! Here is an article about inventor Eric P Gillis:

Title: Eric P Gillis: A Legacy of Innovation and Invention

Introduction:

In the realm of inventions and innovations, Eric P Gillis stands as a beacon of creative spirit and ingenuity. Hailing from Wallingford, CT (US), Gillis has left an indelible mark on the world with his remarkable contributions.

Latest Patents:

With an impressive portfolio of 36 patents, Eric P Gillis' latest patents revolve around groundbreaking advancements in the field of pharmaceuticals. Specifically, his inventions focus on inhibitors of human immunodeficiency virus replication, showcasing his dedication to addressing crucial health challenges.

Career Highlights:

Having worked with esteemed institutions such as Bristol-Myers Squibb Company and the University of Illinois, Gillis has honed his skills and expertise in the pursuit of innovation. His relentless drive to push boundaries and explore new possibilities has led to the development of impactful solutions.

Collaborations:

Throughout his career, Eric P Gillis has collaborated with notable individuals such as Paul Michael Scola and Martin D Burke. These fruitful collaborations have not only enriched his work but have also paved the way for novel inventions and discoveries.

Conclusion:

In conclusion, Eric P Gillis continues to inspire with his inventive spirit, shaping the landscape of inventions and innovations. His dedication to pushing the boundaries of knowledge and creativity serves as a testament to his enduring legacy in the world of patents and inventions.

This text is generated by artificial intelligence and may not be accurate.